Designing Advance Market Commitments for New Vaccines

References

• Acemoglu D, Lim J (2004) Market size in innovation: Theory and evidence from the pharmaceutical industry. Quart. J. Econom. 119(3):1049–1090.Crossref, Google Scholar
• Athey S, Kremer M, Snyder CM, Tabarrok A (2020) In the race for a coronavirus vaccine, we must go big. really, really big. New York Times, May 4, https://www.nytimes.com/2020/05/04/opinion/coronavirus-vaccine.html.Google Scholar
• Berndt ER, Hurvitz JA (2005) Vaccine advance-purchase agreements for low-income countries: Practical issues. Health Affairs 24(3):653–665.Crossref, Google Scholar
• Berndt E, Glennerster R, Kremer M, Lee J, Levine R, Weizsäcker G, Williams H (2007) Advance market commitments for vaccines against neglected diseases: Estimating costs and effectiveness. Health Econom. 16(5):491–511.Crossref, Google Scholar
• Cernuschi T, Furrer E, Schwalbe N, Jones A, Berndt ER, McAdams S (2011) Advance market commitment for pneumococcal vaccines: Putting theory into practice. Bull. World Health Organ. 89:913–918.Crossref, Google Scholar
• Chalkidou K, Kettler H, Ramakrishnan G, Silverman R, Towse A (2020a) Leave No One Behind: Using a Benefit-Based Advance Market Commitment to Incentivise Development and Global Supply of COVID-19 Vaccines (Center for Global Development, Washington, DC).Google Scholar
• Chalkidou K, Towse A, Silverman R, Garau M, Ramakrishnan G (2020b) Market-driven, value-based, advance commitment (MVAC): Accelerating the development of a pathbreaking universal drug regimen to end TB. BMJ Global Health. 5(e002061):1–6.Google Scholar
• Chari VV, Golosov M, Tsyvinski A (2012) Prizes and patents: Using market signals to provide incentives for innovations. J. Econom. Theory 147:781–801.Crossref, Google Scholar
• Department for International Development (2009) Advance market commitments for low-carbon development: an economic assessment. Final report, Department for International Development, London.Google Scholar
• Galasso A, Mitchell M, Virag G (2016) Market outcomes and dynamic patent buyouts. Internat. J. Industry Organ. 48:207–243.Crossref, Google Scholar
• GAVI (2020) COVAX explained. Accessed November 4, 2020, https://www.gavi.org/vaccineswork/covax-explained.Google Scholar
• Kremer M (1998) Patent buyouts: A mechanism for encouraging innovation. Quart. J. Econom. 113(4):1137–1167.Crossref, Google Scholar
• Kremer M (2000a) Creating markets for new vaccines. Part I: Rationale. Innovation Policy Econom. 1:35–72.Crossref, Google Scholar
• Kremer M (2000b) Creating markets for new vaccines. Part II: Design issues. Innovation Policy Econom. 1:73–118.Crossref, Google Scholar
• Kremer M, Glennerster R (2004) Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Disease. (Princeton University Press, Princeton, NJ).Google Scholar
• Kremer M, Williams H (2010) Incentivizing innovation: Adding to the tool kit. Innovation Policy Econom. 10:1–17.Crossref, Google Scholar
• Kremer M, Levin J, Snyder CM (2020) Advance market commitments: Insights from theory and experience. Amer. Econom. Assoc. Papers Proc. 110:269–273.Google Scholar
• Levine R, Kremer M, Albright A (2005) Making Markets for Vaccines: Ideas to Action (Center for Global Development, Washington, DC).Google Scholar
• Light D (2005) Making practical markets for vaccines. PLoS Medicine 2(10):934–938.Crossref, Google Scholar
• Ozawa S, Mirelman A, Stack ML, Walker DG, Levine OS (2012) Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: A systematic review. Vaccine 31(1):96–108.Crossref, Google Scholar
• Ridley DB, Grabowski HG, Moe JL (2006) Developing drugs for developing countries. Health Affairs 25(2):313–324.Crossref, Google Scholar
• Scotchmer S (1999) On the optimality of the patent renewal system. RAND J. Econom. 30:181–196.Crossref, Google Scholar
• Scudellari M (2011) Are advance market commitments for drugs a real advance? Nature Medicine 17(2):139.Crossref, Google Scholar
• Sonderholm J (2011) A theoretical flaw in the advance market commitment idea. J. Medicine Ethics 36:339–343.Crossref, Google Scholar
• Snyder CM, Begor W, Berndt ER (2011) economic perspectives on the advance market commitment for pneumococcal vaccines. Health Affairs 30(8):1508–1517.Crossref, Google Scholar
• Snyder CM, Hoyt K, Gouglas D, Johnston T, Robinson J (2020) Designing pull funding for a COVID-19 vaccine. Health Affairs 39(9):1633–1642.Crossref, Google Scholar
• U.S. Health and Human Services (2020) U.S. government engages Pfizer to produce millions of doses of COVID-19 vaccine. Accessed November 23, 2020, https://www.hhs.gov/about/news/2020/07/22/us-government-engages-pfizer-produce-millions-doses-covid-19-vaccine.html.Google Scholar
• von Braun J, China R, Coulibaly T, Courtney C, Elhaut T, Ghanem H, Jacquet P, et al. (2012) Innovative financing for agriculture, food security, and nutrition. International Expert Report, Leading Group on Innovative Financing to Fund Development, Paris.Google Scholar
• Weyl EG, Tirole J (2012) Market power screens willingness-to-pay. Quart. J. Econom. 127(4):1971–2003.Crossref, Google Scholar
• World Bank and GAVI (2006) Framework document: Pilot AMC for pneumococcal vaccines. Accessed July 3, 2007, http://www.vaccineamc.org/files/Framework Pneumo AMC Pilot.pdf.Google Scholar
• World Health Organization (2007) Pnuemococcal conjugate vaccine for childhood immunization—WHO position paper. Weekly Epidemiology Rec. 82(12):93–104.Google Scholar